Advertisement
Advertisement
U.S. markets close in 4 hours 40 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Amneal Pharmaceuticals, Inc. (AMRX)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
2.1750-0.0550 (-2.47%)
As of 11:19AM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Williams %R

Williams %R

Previous Close2.2300
Open2.1900
Bid2.1700 x 800
Ask2.1800 x 4000
Day's Range2.1550 - 2.2206
52 Week Range2.0000 - 5.9900
Volume226,566
Avg. Volume1,104,960
Market Cap660.167M
Beta (5Y Monthly)1.32
PE Ratio (TTM)217.50
EPS (TTM)0.0100
Earnings DateNov 01, 2022 - Nov 07, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
31% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for AMRX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Amneal Pharmaceuticals, Inc.
    Daily – Vickers Top Buyers & Sellers for 12/20/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    9 months agoArgus Research
View more
  • Business Wire

    Amneal Launches First Biosimilar with ALYMSYS® (bevacizumab-maly) in the United States

    BRIDGEWATER, N.J., October 03, 2022--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) ("Amneal" or the "Company") today announced the commercial launch of ALYMSYS® (bevacizumab-maly), a biosimilar referencing Avastin®. ALYMSYS® is a vascular endothelial growth factor inhibitor used in oncology. This product was developed by mAbxience, a global biotech company with over a decade of experience in the development, manufacture, and commercialization of biopharmaceuticals.

  • Insider Monkey

    10 Best 52-Week Low Small-Cap Stocks to Buy Now

    In this article, we discuss the 10 best 52-week low small-cap stocks to buy now. If you want to skip our discussion on the overall economic environment in the US, go to 5 Best 52-Week Low Small-Cap Stocks to Buy Now. The US stock markets have come under pressure as inflation rose faster than expected […]

  • Business Wire

    Amneal Appoints Gustavo Pesquin as Executive Vice President, Chief Commercial Officer – Specialty

    BRIDGEWATER, N.J., September 06, 2022--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) ("Amneal" or the "Company") today announced it has appointed Gustavo Pesquin as Executive Vice President, Chief Commercial Officer - Specialty, effective September 6, 2022.

Advertisement
Advertisement